Jost Hillenkamp

Dr. Jost Hillenkamp


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Trials
Verified
Journal Article
Open access
PDF file
TJTimothy L. Jackson
Timothy L. Jackson
CBCatey Bunce
Catey Bunce
RDRiti Desai
Riti Desai
JHJost Hillenkamp
Jost Hillenkamp
CLChan Ning Lee
Chan Ning Lee
YWYanzhong Wang
Yanzhong Wang
Background: Neovascular (wet) age-related macular degeneration (AMD) can be associated with large submacular haemorrhage (SMH). The natural history of SMH is very poor, with typically marked and permanent loss of central vision in the affected eye. Practice surveys indicate varied management approaches including observation, intravitreal anti-vascular endothelial growth factor therapy, intravitreal gas to pneumatically displace SMH, intravitreal alteplase (tissue plasminogen activator, TPA) to dissolve the clot, subretinal TPA via vitrectomy, and varying combinations thereof. No large, published, randomised controlled trials have compared these management options. Methods: TIGER is a phase 3, pan-European, two-group, active-control, observer-masked, superiority, randomised controlled surgical trial. Eligible participants have large, fovea-involving SMH of no more than 15 days duration due to treatment-naïve or previously treated neovascular AMD, including idiopathic polypoidal choroidal vasculopathy and retinal angiomatous proliferation. A total of 210 participants are randomised in a 1:1 ratio to pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas and intravitreal aflibercept, or intravitreal aflibercept monotherapy. Aflibercept 2 mg is administered to both groups monthly for 3 doses, then 2-monthly to month 12. The primary efficacy outcome is the proportion of participants with best-corrected visual acuity (BCVA) gain of ≥ 10 Early Treatment Diabetic Retinopathy (ETDRS) letters in the study eye at month 12. Secondary efficacy outcomes (at 6 and 12 months unless noted otherwise) are proportion of participants with a BCVA gain of ≥ 10 ETDRS letters at 6 months, mean ETDRS BCVA, Radner maximum reading speed, National Eye Institute 25-item Visual Function Questionnaire composite score, EQ-5D-5L with vision bolt-on score, Short Warwick and Edinburgh Mental Wellbeing score, scotoma size on Humphrey field analyser, and presence/absence of subfoveal fibrosis and/or atrophy and area of fibrosis/atrophy using independent reading centre multimodal image analysis (12 months only). Key safety outcomes are adverse events, serious adverse events, and important medical events, coded using the Medical Dictionary for Regulatory Activities Preferred Terms. Discussion: The best management of SMH is unknown. TIGER aims to establish if the benefits of SMH surgery outweigh the risks, relative to aflibercept monotherapy. Trial registration: ClinicalTrials.govNCT04663750; EudraCT: 2020-004917-10.

Verified
Journal Article
Open access
PDF file
CBChristina B. Bielmeier
Christina B. Bielmeier
SSSabrina I. Schmitt
Sabrina I. Schmitt
NKNikolai Kleefeldt
Nikolai Kleefeldt
SBStefaniya Boneva
Stefaniya Boneva
ASAnja Schlecht
Anja Schlecht
BBBarbara Braunger
Barbara Braunger
Transforming growth factor β (TGFβ) signaling has manifold functions such as regulation of cell growth, differentiation, migration, and apoptosis. Moreover, there is increasing evidence that it also acts in a neuroprotective manner. We recently showed that TGFβ receptor type 2 (Tgfbr2) is upregulated in retinal neurons and Müller cells during retinal degeneration. In this study we investigated if this upregulation of TGFβ signaling would have functional consequences in protecting retinal neurons. To this end, we analyzed the impact of TGFβ signaling on photoreceptor viability using mice with cell type-specific deletion of Tgfbr2 in retinal neurons and Müller cells (Tgfbr2ΔOC) in combination with a genetic model of photoreceptor degeneration (VPP). We examined retinal morphology and the degree of photoreceptor degeneration, as well as alterations of the retinal transcriptome. In summary, retinal morphology was not altered due to TGFβ signaling deficiency. In contrast, VPP-induced photoreceptor degeneration was drastically exacerbated in double mutant mice (Tgfbr2ΔOC; VPP) by induction of pro-apoptotic genes and dysregulation of the MAP kinase pathway. Therefore, TGFβ signaling in retinal neurons and Müller cells exhibits a neuroprotective effect and might pose promising therapeutic options to attenuate photoreceptor degeneration in humans.

22 September 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JTJohanna Theuersbacher
Johanna Theuersbacher
LHLukas Haug
Lukas Haug
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
GWGrit Walther
Grit Walther
OKOliver Kurzai
Oliver Kurzai
JHJost Hillenkamp
Jost Hillenkamp
Fungal keratitis is a severe infection that often requires surgical intervention and is associated with poor outcomes. Penetrating keratoplasty allows for the complete removal of the fungal infiltrate and thus can be a turning point in therapy. The depth of pathogen invasion, which cannot always be reliably assessed by slit lamp examination, can be accurately determined through histological analysis of the corneal trephinate. In this study, we histologically analyzed two corneal trephinates obtained during an emergency keratoplasty performed for uncontrollable mycotic infections. In case 1, caused by Candida albicans, the infiltrate remained localized at the site of pathogen entry. In contrast, in case 2, Fusarium falciforme demonstrated extensive tissue invasion, spreading destructively throughout the cornea. This invasion pattern suggests that Fusarium keratitis is difficult to control due to its aggressive spreading behavior within the tissue. This explains the high rate of penetrating keratoplasty required in such cases.

2 August 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMohamad Dakroub
Mohamad Dakroub
MBMarina Barkhuysen
Marina Barkhuysen
RVRaoul Verma-Fuehring
Raoul Verma-Fuehring
ABAhmed Bamousa
Ahmed Bamousa
JHJost Hillenkamp
Jost Hillenkamp
NLNils Loewen
Nils Loewen
Purpose: We hypothesized that a recently introduced epibulbar micro-shunt (PRESERFLO, P) produces nycthemeral (24h) intraocular pressure (IOP) profiles different from ab-interno trabeculectomy (Trabectome, T). P is a flow restrictor that drains fluid into the sub-tenon space. In contrast, T increases conventional outflow, which is limited by episcleral venous pressure. Methods: In this prospective cohort, we analyzed 68 patients (34 P and 34 T) who presented for 24-h IOP monitoring 6 to 12 months after surgery. IOP and tonographic outflow facility were measured in the habitual position using a pneumatonometer. The IOP variation was considered the primary outcome measure. Glaucoma medications were also compared. Results: P had a higher baseline IOP than T (24.8±10.0 vs. 17.3±7.9 mmHg, p=0.001). Postoperatively, P and T had similar nycthemeral IOP profiles, but IOP in P was significantly lower than in T, except at 4 pm. P had a lower absolute IOP variation than T (5.8±2.6 vs. 7.1±2.7 mmHg, p=0.049). The relative IOP variation was similar in both (34.8±13.2 vs. 37.2±13.1, p=0.45) as was the tonographic outflow facility (0.35±0.23 vs. 0.26±0.18 µl/min/mmHg, p=0.097). Conclusion: Nycthemeral IOP profiles of P and T were similar, but P had lower IOPs and less variation than T. This could reflect how T, unlike P, is more impacted by habitual, positional factors, especially at night.